Otros idiomas ACADIA Pharmaceuticals Inc.

Acciones

ACAD

US0042251084

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
16,71 ^USD	+2,45 %		-0,65 %	-46,63 %

22/04	Acadia Pharmaceuticals Inc anuncia que Health Canada ha aceptado la presentación del nuevo fármaco trofinetida para el tratamiento del síndrome de Rett para su presentación y revisión prioritaria	CI
17/04	ACADIA Pharmaceuticals Inc. presenta nuevos datos clínicos de DAYBUE (trofinetida) en la reunión anual de 2024 de la Academia Americana de Neurología	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024	24/04
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	23/04
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	22/04
Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	22/04
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada	22/04
Acadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé Canada	22/04
Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada	22/04
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19/04
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting	17/04
ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting	17/04
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development	02/04
ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development	02/04
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	01/04
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing	28/03
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 15, 2024	18/03
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	15/03
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day	13/03
North American Morning Briefing : Stock Futures -2-	13/03
Sector Update: Health Care Stocks Gain Premarket Tuesday	12/03
Aktien New York Ausblick: Gewinne erwartet nach Inflationsdaten	12/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas ACADIA Pharmaceuticals Inc.

Acciones

ACAD

US0042251084

Otros idiomas

Filtros